Clinical trial · Interventional
RGD-PET-CT in Cancer Angiogenesis
Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT
NCT01492192CI-TRIAL-00030153terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that attack tumour blood supply.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-RGD-PET-CT and perfusion CT scans on 3 occasions | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- RCC Patients Antiangiogenic treatment
- interventionNames
- Drug: 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
Primary outcomes (1)
- measure
- Changes in tumour uptake of the fluciclatide imaging agent
- timeFrame
- Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
- description
- % change in SUVmax
Secondary outcomes (6)
- measure
- Tumour response within an individual patient
- timeFrame
- Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
- description
- % change in size
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients should have advanced or metastatic RCC confirmed by histological diagnosis 2. Patients considered suitable for therapy with TKI for RCC according to responsible clinician 3. Measurable tumour according to RECIST v1.1 criteria 4. Standard staging CT scan performed within 28 days of first research scan 5. The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment 6. Age ≥18 years 7. Adequate renal function (creatinine \<1.25xULN) 8. Patient is able to tolerate and comply with scanning procedure 9. Patient is not lactating or pregnant 10. Absence of any psychological, familial, sociological or geographical condition which in the opinion of the Investigator may potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial 11. Able and willing to give informed consent Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.